Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 24 results.
User Information
Export Records
  1. 1.   Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
  2. Hong, Jaewoo; Jhun, Hyunjhung; Choi, Yeo-Ok; Taitt, Afeisha S.; Bae, Suyoung; Lee, Youngmin; Song, Chang-seon; Yeom, Su Cheong; Kim, Soohyun
  3. Immune Network. 2021, Feb 19; 21(1):
  1. 2.   Novel Chalcone Derivatives as Potent Nrf2 Activators in Mice and Human Lung Epithelial Cells
  2. Kumar, V.; Kumar, S.; Hassan, M.; Wu, H. L.; Thimmulappa, R. K.; Kumar, A.; Sharma, S. K.; Parmar, V. S.; Biswal, S.; Malhotra, S. V.
  3. Journal of Medicinal Chemistry. 2011, Jun; 54(12): 4147-4159.
  1. 3.   Intervening in beta-Catenin Signaling by Sulindac Inhibits S100A4-Dependent Colon Cancer Metastasis
  2. Stein, U.; Arlt, F.; Smith, J.; Sack, U.; Herrmann, P.; Walther, W.; Lemm, M.; Fichtner, I.; Shoemaker, R. H.; Schlag, P. M.
  3. Neoplasia. 2011, Feb; 13(2): 131-144.
  1. 4.   Resveratrol differentially modulates inflammatory responses of microglia and astrocytes
  2. Lu, X. F.; Ma, L. L.; Ruan, L. F.; Kong, Y.; Mou, H. W.; Zhang, Z. J.; Wang, Z. J.; Wang, J. M.; Le, Y. Y.
  3. Journal of Neuroinflammation. 2010, Aug; 7: 14.
  1. 5.   Cyclooxygenase-2 Polymorphisms, Aspirin Treatment, and Risk for Colorectal Adenoma Recurrence-Data from a Randomized Clinical Trial
  2. Barry, E. L.; Sansbury, L. B.; Grau, M. V.; Ali, I. U.; Tsang, S.; Munroe, D. J.; Ahnen, D. J.; Sandler, R. S.; Saibil, F.; Gui, J.; Bresalier, R. S.; McKeown-Eyssen, G. E.; Burke, C.; Baron, J. A.
  3. Cancer Epidemiology Biomarkers & Prevention. 2009 18(10): 2726-2733.
  1. 6.   Aerosol-delivered programmed cell death 4 enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice
  2. Hwang, S. K.; Jin, H.; Kwon, J. T.; Chang, S. H.; Kim, T. H.; Cho, C. S.; Lee, K. H.; Young, M. R.; Colburn, N. H.; Beck, G. R.; Yang, H. S.; Cho, M. H.
  3. Gene Therapy. 2007, Sep; 14(18): 1353-1361.
  1. 7.   Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator
  2. Hurt, E. M.; Thomas, S. B.; Peng, B.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2006, Sep; 5(9): 1154-1160.
  1. 8.   Natural products from marine invertebrates and microbes as modulators of antitumor targets
  2. Newman, D. J.; Cragg, G. M.
  3. Current Drug Targets. 2006, MAR; 7(3): 279-304.
  1. 9.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 10.   Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: Molecular targets are TBK1 and RIP1 in TRIF complex
  2. Youn, H. S.; Lee, J. Y.; Fitzgerald, K. A.; Young, H. A.; Akira, S.; Hwang, D. H.
  3. Journal of Immunology. 2005, SEP 1; 175(5): 3339-3346.
  1. 11.   Constitutive expression of functional CD40 on mouse renal cancer cells: Induction of Fas and Fas-mediated killing by CD40L
  2. Lee, J. K.; Seki, N.; Sayers, T. J.; Subleski, J.; Gruys, E. M.; Murphy, W. J.; Wiltrout, R. H.
  3. Cellular Immunology. 2005, JUN; 235(2): 145-152.
  1. 12.   Formylpeptide receptor FPR and the rapid growth of malignant human gliomas
  2. Zhou, Y.; Bian, X. W.; Le, Y. Y.; Gong, W. H.; Hu, J. Y.; Zhang, X.; Wang, L. H.; Iribarren, P.; Salcedo, R.; Howard, O. M. Z.; Farrar, W.; Wang, J. M.
  3. Journal of the National Cancer Institute. 2005, JUN 1; 97(11): 823-835.
  1. 13.   Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small-molecule screening and structural databases
  2. Covell, D. G.; Wallqvist, A.; Huang, R. L.; Thanki, N.; Rabow, A. A.; Lu, X. J.
  3. Proteins-Structure Function and Bioinformatics. 2005, MAY 15; 59(3): 403-433.
  1. 14.   A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors
  2. Daelemans, D.; Pannecouque, C.; Pavlakis, G. N.; Tabarrini, O.; De Clercq, E.
  3. Molecular Pharmacology. 2005, MAY; 67(5): 1574-1580.
  1. 15.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 16.   Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-Lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
  2. Nellis, D. F.; Giardina, S. L.; Janini, G. M.; Shenoy, S. R.; Marks, J. D.; Tsai, R.; Drummond, D. C.; Hong, K.; Park, J. W.; Ouellette, T. F.; Perkins, S. C.; Kirpotin, D. B.
  3. Biotechnology Progress. 2005, JAN-FEB; 21(1): 221-232.
  1. 17.   Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappa B activation and transformation in resistant JB6 cells
  2. Hu, J.; Nakano, H.; Sakurai, H.; Colburn, N. H.
  3. Carcinogenesis. 2004, OCT; 25(10): 1991-2003.
  1. 18.   Regulating the p53 system through ubiquitination
  2. Yang, Y. L.; Li, C. C. H.; Weissman, A. M.
  3. Oncogene. 2004 23(11): 2096-2106.
  1. 19.   A potential role for imaging technology in anticancer efficacy evaluations
  2. Hollingshead, M. G.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Shoemaker, R.; Melillo, G.; Sausville, E. A.
  3. European Journal of Cancer. 2004 40(6): 890-898.
  1. 20.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 21.   The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen- activated protein kinase activity
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Mihalic, K.; Xiao, W. H.; Farrar, W. L.
  3. Cancer Research. 2003 63(9): 2046-2051.
  1. 22.   wmc79 and hkh40a - Potent agents against gastrointestinal cancers: Molecular targets and mechanism of action
  2. Kosakowska-Cholody, T.; Cholody, W. M.; Hariprakasha, H. K.; Michejda, C. J.; Hollingshead, M. G.; Pommier, Y.; Antony, S.; Kar, S.; Carr, B. I.
  3. Clinical Cancer Research. 2003 9(16): 6077S-6078S.
  1. 23.   RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer
  2. Fang, S.; Lorick, K. L.; Jensen, J. P.; Weissman, A. M.
  3. Seminars in Cancer Biology. 2003 13(1): 5-14.
  1. 24.   Natural product drug discovery in the next millennium
  2. Cragg, G. M.; Newman, D. J.
  3. Pharmaceutical Biology. 2001 39(Suppl. S): 8-17.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel